Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R, Xu L, Che L, Liu S, Wang Y, Dong B.
Front Endocrinol (Lausanne). 2023 Feb 13;14:1125693. doi: 10.3389/fendo.2023.1125693. eCollection 2023.
Mitochondrial Dysfunction in Kidney Tubulopathies.
Hoogstraten CA, Hoenderop JG, de Baaij JHF.
Annu Rev Physiol. 2024 Feb 12;86:379-403. doi: 10.1146/annurev-physiol-042222-025000. Epub 2023 Nov 27.
Prevalence of primary aldosteronism among patients with type 2 diabetes.
Tancredi M, Johannsson G, Eliasson B, Eggertsen R, Lindblad U, Dahlqvist S, Imberg H, Lind M.
Clin Endocrinol (Oxf). 2017 Sep;87(3):233-241. doi: 10.1111/cen.13370. Epub 2017 Jun 21.
A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.
Zhai S, Ma B, Chen W, Zhao Q.
Front Cardiovasc Med. 2024 Sep 23;11:1476029. doi: 10.3389/fcvm.2024.1476029. eCollection 2024.
Prevalence of Normal-Tension Glaucoma in Patients With Primary Aldosteronism.
Hirooka K, Higashide T, Sakaguchi K, Udagawa S, Sugiyama K, Oki K, Kometani M, Yoneda T, Fukunaga K, Akita T, Baba T, Kiuchi Y.
Am J Ophthalmol. 2025 Jan;269:339-345. doi: 10.1016/j.ajo.2024.09.014. Epub 2024 Sep 14.
Blood flow in the optic nerve head in patients with primary aldosteronism.
Hirooka K, Oki K, Ogawa-Ochiai K, Nakaniida Y, Onoe H, Kiuchi Y.
PLoS One. 2023 Apr 26;18(4):e0285039. doi: 10.1371/journal.pone.0285039. eCollection 2023.
Unusual presentation of primary aldosteronism with advanced target organ damage: A case report.
Fava C, Cattazzo F, Bernasconi R, Romano S, Minuz P.
Radiol Case Rep. 2019 Apr 18;14(7):814-818. doi: 10.1016/j.radcr.2019.04.011. eCollection 2019 Jul.
Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats.
Kurtz M, Fabrès V, Dumont R, Chetboul V, Chahory S, Saponaro V, Trehiou E, Poissonnier C, Passavin P, Jondeau C, Bott M, Buronfosse T, Benchekroun G.
J Vet Intern Med. 2023 Jul-Aug;37(4):1348-1357. doi: 10.1111/jvim.16741. Epub 2023 May 29.
A Case Report of Primary Aldosteronism and Extensive Hypertension-Mediated Organ Damage.
Brum de Sousa E, do Mar Menezes M, Cordeiro AM.
Cureus. 2024 Feb 8;16(2):e53818. doi: 10.7759/cureus.53818. eCollection 2024 Feb.
Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.
Tan ST, Boyle V, Elston MS.
Hypertension. 2023 Jul;80(7):1517-1525. doi: 10.1161/HYPERTENSIONAHA.123.21054. Epub 2023 May 12.
